Strategic fundraising SanBio has recently secured substantial financing, including a 102 million USD-equivalent raise and 16.2 billion yen in approval-related funding, signaling strong investor confidence and potential for rapid expansion or collaborative development initiatives.

Partnerships & Licensing Historically, SanBio has engaged in multiple high-profile partnerships with Hitachi Chemical, Sumitomo Dainippon Pharma, and Sunovion, indicating openness to co-development, licensing, and manufacturing partnerships that could be accelerated for new markets or indications.

Global expansion With ongoing clinical development in Japan and the US for SB623 and plans to expand indications and geographic regions, there are immediate opportunities to pursue regional distributors, contract manufacturing, and regulatory co-development arrangements in new territories.

Regenerative medicine focus SanBio specializes in regenerative cell medicines for central nervous system disorders with limited existing therapies, suggesting potential to target hospitals, academic centers, and CNS-focused clinics seeking innovative disease-modifying treatments.

Clinical & manufacturing readiness Strategic emphasis on rapid commercialization and established manufacturing collaborations positions SanBio for partnerships around clinical trials, real-world evidence programs, and scalable supply agreements to support phase progression and market launch.